Phase 2 Study of Pembrolizumab and Circulating Biomarkers to Predict Anticancer Response in Advanced, Unresectable Hepatocellular Carcinoma

BACKGROUND: Checkpoint inhibitors have shown modest activity in patients with advanced hepatocellular carcinoma (HCC). Herein, the authors report a prospective single-institution clinical/translational phase 2 study of pembrolizumab in patients with advanced HCC and circulating biomarkers closely re...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer
Main Authors: Feun, Lynn G., Li, Ying-Ying, Wu, Chunjing, Wangpaichitr, Medhi, Jones, Patricia D., Richman, Stephen P., Madrazo, Beatrice, Kwon, Deukwoo, Garcia-Buitrago, Monica, Martin, Paul, Hosein, Peter J., Savaraj, Niramol
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7592647/
https://ncbi.nlm.nih.gov/pubmed/31251403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32339
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki